- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07951762
A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.
An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.
This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.
Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.
The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Jian Zhang
- Telefonnummer: 021-64175590
- E-Mail: syner2000@163.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
- Age 18-75 (inclusive) years;
- Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
- Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
- Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
- Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
- Life expectancy ≥ 3 months;
- Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.
Exclusion Criteria:
- Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
- Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
- Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
- Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
- Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
- History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: SYS6043+PD-1/VEGF bispecific antibody
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV |
|
Experimental: SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV |
|
Experimental: SYS6043 monotherapy
|
SYS6043: IV |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase I: Incidences of AEs
Zeitfenster: From the signing of the informed consent form until 90 days after the last dose.
|
From the signing of the informed consent form until 90 days after the last dose.
|
|
|
Phase I: DLT
Zeitfenster: 21 days
|
Dose-limiting toxicity |
21 days
|
|
Phase I: MTD/RP2D
Zeitfenster: After phase I dose escalation stage. Approximately 4 months.
|
Maximum Tolerated Dose/ Recommended Phase II Dose |
After phase I dose escalation stage. Approximately 4 months.
|
|
Phase II: ORR
Zeitfenster: Up to 2 years
|
Objective response rate |
Up to 2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase I: ORR
Zeitfenster: Up to 2 years
|
Objective response rate |
Up to 2 years
|
|
Phase I:DCR
Zeitfenster: Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase I:DOR
Zeitfenster: Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase I: TTR
Zeitfenster: Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase I: PFS
Zeitfenster: Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase I:OS
Zeitfenster: Up to 3 years
|
Overall survival |
Up to 3 years
|
|
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:DCR
Zeitfenster: Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase II:DOR
Zeitfenster: Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase II: TTR
Zeitfenster: Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase II: PFS
Zeitfenster: Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase II:OS
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Title: Phase II: Incidences of AEs
Zeitfenster: From the signing of the informed consent form until 90 days after the last dose.
|
Overall survival |
From the signing of the informed consent form until 90 days after the last dose.
|
|
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- SYS6043-005
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .